相关实验视频
Updated: Jul 27, 2025

07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
451
风险因素和免疫调节剂在类固醇耐药检查点抑制剂肺炎中的使用
Yanlin Li1, Xiaohui Jia1, Yajuan Zhang1
1Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China sunhong2023@xjtu.edu.com
Journal for immunotherapy of cancer
|June 8, 2023
概括
类固醇耐药检查点抑制性肺炎 (CIP) 与更高程度的疾病和中性粒细胞数量的增加有关. 免疫调节剂可以改善严重 (3-4级) 类固醇耐药性CIP的结果.
科学领域:
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
背景情况:
- 检查点抑制性肺炎 (CIP) 是癌症免疫治疗中的一个重大不良事件.
- 类固醇耐火性CIP (SR-CIP) 由于对标准皮质类固醇治疗的反应不佳,提出了临床挑战.
- 识别SR-CIP的风险因素和优化管理对于患者的治疗结果至关重要.
研究的目的:
- 为了确定与类固醇耐火性CIP的发展相关的风险因素.
- 评估免疫调节剂 (IMs) 作为SR-CIP的管理策略的疗效.
- 为管理CIP的临床决策提供见解.
主要方法:
- 在2019年8月至2022年8月期间对CIP患者的回顾性分析.
- 收集临床特征,外围血液生物标志物和放射图像.
- 多变量分析以确定SR-CIP的独立风险因素.
主要成果:
- 患有SR-CIP的患者在诊断时有更高的先前间歇性肺病和3-4级CIP的发病率.
- 在SR-CIP患者中观察到较高的绝对中性粒细胞数 (ANC) 和前素,以及较低的白蛋白.
- 诊断时的3-4级CIP和更高的ANC是SR-CIP的独立风险因素.
- 额外的免疫调节剂并没有改善2级SR-CIP的预后,但显著减少了3-4级SR-CIP的恶化.
结论:
- 高度CIP (3-4) 和在诊断时升高的外周血液ANC与耐固醇CIP的风险增加有关.
- 使用额外的免疫调节剂可以改善3-4级类固醇耐药性CIP患者的治疗结果.
- 这些发现有助于对CIP患者的临床管理决策.
更多相关视频
相关概念视频
Pulmonary Tuberculosis I
288
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
288
Drugs Used in Lower Respiratory Disorders: Overview
506
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
506
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.8K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.8K
COPD: Pathogenesis and Clinical Features
368
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
368
COPD: Management Using Bronchodilators and Corticosteroids
255
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
255
Pneumonia III: Complications and Assessment
287
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
287

